3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Terminated
3
Completed
3
Withdrawn
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Head & Neck
4
Dermatologic
3
Sarcoma
2
Genitourinary
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Melanoma
3
Recurrence
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
58
Ipilimumab
53
Cyclophosphamide
53
Nivolumab
45
aldesleukin
35
Interleukin-2
26
fludarabine phosphate
22
fludarabine
21
Vemurafenib
20
Temozolomide
19
Radiotherapy
19
dabrafenib
15
trametinib
12
Radiosurgery
11
CTLA-4 Antigen
11
spartalizumab
10
Filgrastim
10
Dacarbazine
10
cobimetinib
9
binimetinib
9
atezolizumab
9
Biopsy
9
poly ICLC
8
Paclitaxel
8
Antilymphocyte Serum
8
encorafenib
7
avelumab
7
Rituximab
7
Introns
7
romidepsin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Terminated
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT04410445
2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3
Terminated
765 enrolled
13 charts
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts